# SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

> **NCT05093387** · PHASE1 · WITHDRAWN · sponsor: **Northwestern University**

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Breast Inflammatory Carcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Prognostic Stage IV Breast Cancer AJCC v8

## Interventions

- **DRUG:** Carboplatin
- **BIOLOGICAL:** Pembrolizumab
- **GENETIC:** Transferrin Receptor-Targeted Liposomal p53 cDNA

## Key facts

- **NCT ID:** NCT05093387
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-10
- **Primary completion:** 2022-11-10
- **Final completion:** 2022-11-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** funding issues and pharmacy preparation for the drug
- **Last updated:** 2022-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05093387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05093387, "SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05093387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*